Cellectar Biosciences (CLRB) Reports Positive Data from Phase 1 Orphan Drug Study, Moves to Dose Escalation
Oncology-focused biotech Cellectar Biosciences (NASDAQ: CLRB) reports an “outstanding safety profile” from the second cohort of patients enrolled in its orphan-drug designated phase I study of CLR 131 in patients with relapsed or refractory multiple myeloma. Based on these positive results, the study’s Data Monitoring Committee approved patient enrollment to the third cohort, which will include a 33% dose increase from the previous cohort. In the multi-center, open label phase I dose escalation study, CLR 131 is administered as a single dose, 30-minute infusion. The primary study objective is to characterize the safety and tolerability of CLR 131 in patients…







